- Generic name
- Streptokinase
- Strength
- 15 Lac IU
- Dosage form
- Injection
- Manufactured by
- Advanced Chemical Industries PLC
Streptokinase IV Injection
About Streptokinase IV 15 Lac IU Injection
Streptokinase IV is a 15 Lac IU injection made by Advanced Chemical Industries PLC. It is a fibrinolytic (thrombolytic) medicine given by a doctor in a hospital setting to help break down blood clots.
What is Streptokinase IV 15 Lac IU Injection?
Streptokinase IV 15 Lac IU is an injectable fibrinolytic (thrombolytic) medicine from Advanced Chemical Industries PLC. It works by helping the body turn plasminogen into plasmin, which breaks down clots. It is used in hospital for conditions such as acute myocardial infarction and for dissolving intracoronary thrombi. Because it affects clotting and bleeding, it is given under close medical supervision. Only a qualified doctor decides whether it is suitable, how it is prepared and how it is given. Ask the treating doctor or pharmacist about anything you do not understand.
Uses of Streptokinase IV
Streptokinase IV is used in the management of acute myocardial infarction and for the lysis of intracoronary thrombi. It is also used to improve ventricular function and to reduce mortality when given by the intravenous or intracoronary route. It belongs to the fibrinolytic (thrombolytic) group of medicines, which help break down blood clots. Only a doctor can decide whether this medicine is appropriate for a particular patient.
How to use Streptokinase IV
Streptokinase IV 15 Lac IU is given by a doctor or trained hospital staff, usually as an infusion into a vein or, in some cases, into a coronary artery. It is prepared by reconstitution before use. The doctor decides the dose, the rate and the length of the course, and adjusts them to the patient. Do not attempt to use or prepare this injection yourself. Ask the doctor or pharmacist if you have questions about how it is being given.
Side effects of Streptokinase IV
Common side effects include headache, back pain, muscle pain, chills, fever and a general feeling of tiredness. Bleeding can occur, including at the injection site, bruising, nosebleeds, and gastrointestinal or genitourinary bleeding. Less common but serious effects include bleeding inside the skull and other severe bleeding. Because of these risks, treatment is given with close medical monitoring. Tell the doctor or nurse straight away about any unusual bleeding, fever or feeling unwell during or after treatment.
Safety and precautions
Streptokinase IV increases the risk of bleeding, so it is not suitable for people with existing or recent bleeding, bleeding disorders, a potential for internal bleeding, or reduced blood clotting. It is also not used after a recent stroke or recent head or facial injury, or after certain surgery. Pregnancy is category C, and it is not known whether it passes into breast milk; breastfeeding is usually stopped while a woman receives it. Tell the doctor about all medicines you take, including blood thinners, and about any past streptococcal infection or earlier streptokinase treatment. The doctor decides if it is safe for you.
Frequently asked questions
How is Streptokinase IV given?
It is given by a doctor or hospital staff, usually as an infusion into a vein or into a coronary artery, after being prepared by reconstitution. The doctor decides the dose, the rate and the length of the course. Do not use it yourself.
What is Streptokinase IV used for and what kind of medicine is it?
It is a fibrinolytic (thrombolytic) medicine. It is used in hospital in the management of acute myocardial infarction and for dissolving intracoronary thrombi, and to improve ventricular function and reduce mortality when given by the intravenous or intracoronary route.
Is Streptokinase IV safe in pregnancy or breastfeeding?
It is pregnancy category C. It is not known whether it passes into breast milk, so breastfeeding is usually stopped while a woman receives it. Tell the doctor if you are pregnant, may be pregnant or are breastfeeding, and the doctor will decide what is suitable.
What should I tell the doctor before receiving Streptokinase IV?
Tell the doctor about any bleeding problems, recent stroke, recent head or facial injury, recent surgery, and all medicines you take, especially blood thinners. Also mention any past streptococcal infection or earlier streptokinase treatment, as these can affect how well it works.
Indications
Pharmacology
Dosage & Administration
Acute Myocardial Infarction:
IV infusion:- Vial size (IU): 15,00,000
- Total solution volume: 45 ml
- Infusion rate: Infuse 45 ml within 60 mins
- Vial size (IU): 2,50,000
- Total solution volume: 125 ml
- 20,000 IU bolus, Infusion rate: Loading dose of 10 ml
- 2,000 IU/min. for 60 minutes, Infusion rate: 60 ml/hour
Pulmonary Embolism, Deep Vein Thrombosis, Arterial Thrombosis or Embolism:
- 2,50,000 IU loading dose over 30 min, Vial size (IU): 15,00,000, Total solution volume 90 ml, Infusion rate: Infuse 30 ml/hour for 30 min
- 1,00,000 IU/hour for maintenance dose, Infusion rate: Infuse 6 ml/hour
Interaction
Combination of Streptokinase with Aspirin for treatment of Myocardial infarction: Study showed a significant benefit to patients treated with these two agents after acute myocardial infarction. Mortality (both short and longer term) was reduced in these patients to a greater extent than in those treated with either agent alone.
Unless contraindicated, the concomitant use of Acetylsalicylic acid (ASA, Aspirin), starting prior to Streptokinase infusion and continued for one month thereafter may be instituted at the discretion of the physician. The benefit of combination therapy should therefore be weighed against the risk of increased haemorrhage.
Anticoagulation treatment following Streptokinase: Following high dose (1.5 million IU), short term treatment with Streptokinase, for acute myocardial infarction, the use of subsequent anticoagulant treatment has not yet been shown to be of unequivocal benefit. Therefore, in this situation, the use of anticoagulants should be decided by the physician.
Contraindications
Existing or recent haemorrhage and haemorrhagic diathesis (with the exception of consumption coagulopathy) Potential for internal bleeding (e.g., peptic ulcer, ulcerative colitis, diverticulitis or visceral tumours) All forms of reduced blood coagulability, in particular spontaneous fibrinolysis and extensive clotting disorders.
Recent (within 2 months) cerebrovascular accident, recent (within 10 days) facial or head trauma, intracranial or intraspinal surgery, known intracranial neoplasm and all known neoplasms with risk of haemorrhage
Invasive operations, e.g., recent organ biopsy, invasive diagnostic procedure, recent implantation of a vessel prosthesis, long-term traumatic closed-chest massage or other recent surgery (until the 6th to 10th post operative day, depending on the severity of surgical intervention)
Arteriovenous malformation or aneurysm: Haemorrhagic diathesis including thrombocytopenia or pronounced hepatic or renal dysfunction
Severe uncontrolled hypertension (systolic BP > 200 mm Hg, diastolic BP > 100 mm Hg), or hypertensive retinal changes grades III/IV), hypertonic fundus
Severe liver or kidney damage: Simultaneous treatment with oral anticoagulants (International Normalized Ratio (INR) >1.3)
Endocarditis or pericarditis (Immediately after streptococcal infections which have produced a high antiStreptokinase titre (acute rheumatic fever, acute glomerulo-nephritis, etc.). More than 5 days and less than 12 months since previous Streptokinase therapy.
Side Effects
General disorders:
- Common: Headache and back pain, muscle pain (including myalgia), chills and/or fever as well as asthenia/malaise.
- Common: Haemorrhages at invaded or disturbed sites, including the injection site, and ecchymoses. Gastrointestinal or genitourinary bleedings (including aggravation of menstrual bleeding), epistaxis.
- Uncommon: Intracranial haemorrhages with their complications and possible fatal outcome, retinal haemorrhages, severe haemorrhages (also with fatal outcome) including liver haemorrhages, retroperitoneal bleedings, splenic rupture. Blood transfusions are rarely required.
- Very common: Development of antistreptokinase antibodies
- Common: Allergic-anaphylactic reactions such as rash, flushing, itching, urticaria, angioneurotic oedema, minor breathing difficulty, periorbital swelling, bronchospasm or hypotension.
- Rare: Neurologic symptoms (e.g., dizziness, confusion, paralysis, hemiparesis, agitation or convulsion) in the context of cerebral haemorrhages or cardiovascular disorders with hypoperfusion of the brain.
- Very common: Hypotension, heart rate and rhythm disorders, angina pectoris.
- Common: Recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema.
- Uncommon: Cardiac arrest (leading to respiratory arrest), mitral insufficiency, pericardial effusion, cardiac tamponade, myocardial rupture, pulmonary or distal embolism.
- Very rare: Non-cardiogenic pulmonary oedema after intracoronary thrombolytic therapy in patients with extensive myocardial infarction.
- Common: Nausea, diarrhoea, epigastric pain and vomiting.
Pregnancy & Lactation
Precautions & Warnings
In principle, no thrombolytic treatment should be commenced before the 10th postoperative day. However, in cases of pulmonary embolism, the indication for earlier treatment may be very strong and after careful consideration of all the risks, Streptokinase may be given before the tenth postoperative day. The danger of bleeding from the operative area must, of course, be taken into account.
The danger of haemorrhage is increased by simultaneous or previous treatment with anticoagulants (e.g., Heparin) or substances which inhibit platelet formation or function. If the patient is under active heparinisation, it should be neutralised by the administration of protamine sulphate before the start of thrombolytic therapy.
Repeated Administration: After administration of Streptokinase, the titre of antistreptokinase antibodies begins to rise after approximately one week, reaching a peak at 2 to 3 weeks and remains elevated for 8 to 12 months. Because of the increased likelihood of resistance, Streptokinase may not be effective if given during this period.
Overdose Effects
Storage Conditions
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.